252 related articles for article (PubMed ID: 21848202)
1. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
Morrow T
Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
Stranges PM; Hutton DW; Collins CD
Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Hardesty JS; Juang P
Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
[TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
Soriano MM; Liao S; Danziger LH
Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
Simon MS
Clin Infect Dis; 2014 Feb; 58(4):603. PubMed ID: 24300043
[No Abstract] [Full Text] [Related]
6. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Miller M
Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
19. Role of fidaxomicin for the treatment of Clostridium difficile infection.
Juang P; Hardesty JS
J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
Venugopal AA; Johnson S
Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
